Search tips
Search criteria 


Logo of neuroscibullNeuroscience Bulletin
Neurosci Bull. 2007 January; 23(1): 41–45.
Published online 2007 December 15. doi:  10.1007/s12264-007-0006-1
PMCID: PMC5550567

Language: English | Chinese

Negative correlation of Nogo-A with the malignancy of oligodendroglial tumor

Nogo-A 蛋白的表达与少突胶质细胞肿瘤恶性程度呈负相关



Nogo-A is an axon regeneration inhibitor, and its function in central nervous system (CNS) is still unknown. The present study is to explore the relationship between the expression of Nogo-A and the malignancy of oligodendroglial tumors in patients.


Tumor tissue samples with different malignancy grade were obtained from the hospitals. The samples used for detection had been diagnosed as oligodendroglial tumors (oligodendroglioma or anaplastic oligodendroglioma). The expression of Nogo-A was detected by immunohistochemistry and western-blot analysis. The correlation test between the Nogo-A expression and the morphological changes (the percentages of atypical cells and mitotic cells in the tumors) related to the malignancy of tumor tissues was performed.


There was significant negative correlation between the Nogo-A expression and the morphological change of tumor tissues according to immunohistochemistry. Western-blot analysis also indicated that the gray value of Nogo-A protein band in the oligodendroglioma group was significantly higher than that in the anaplastic oligodendroglioma group.


Nogo-A expression was negatively correlated with the malignancy grade of oligodendroglial tumors.

Keywords: Nogo-A, oligodendroglial tumors, immunohistochemistry



探讨 Nogo-A 蛋白在少突胶质细胞肿瘤中的表达水平与该肿瘤恶性程度之间的关系。


选取来自临床上经病理检查确诊为少突胶质细胞肿瘤的组织标本, 其中少突胶质细胞瘤 16 例, 间变型少突胶质细胞瘤 10 例。 免疫组织化学染色检测 Nogo-A 的表达, 并与同视野下瘤细胞的核分裂与核异型性比例作相关分析; 另外, 把病理标本按照分级进行蛋白印迹 试验。


免疫组织化学结果显示, Nogo-A 免疫阳性染色的光密度值与肿瘤细胞核分裂、 核异型比例呈明显的负相关, 对蛋白印迹试验结果进行光密度分析也发现少突胶质细胞瘤中的 Nogo-A 蛋白条带灰度值明显高于间变型少突胶质细胞瘤中的灰度值。


Nogo-A 蛋白在少突胶质细胞肿瘤中的表达水平与该肿瘤恶性程度呈负相关。

关键词: Nogo-A, 少突胶质细胞肿瘤, 免疫组织化学


[1] GrandPre T., Nakamura F., Vartanian T., Strittmatter S.M. Identification of the Nogo inhibitor of axon regeneration as a Reticulon protein. Nature. 2000;403:439–444. doi: 10.1038/35000226. [PubMed] [Cross Ref]
[2] Chen M.S., Huber A.B., van der Haar M.E., Frank M., Schnell L., Spillmann A.A. Nogo-A is a myelin-associated neurite outgrowth inhibitor and an antigen for monoclonal antibody IN-1. Nature. 2000;27:403. [PubMed]
[3] Li Q., Qi B., Oka K., Shimakage M., Yoshioka N., Inoue H. Link of a new type of apoptosis-inducing gene ASY/Nogo-B to human cancer. Oncogene. 2001;20:3929–3936. doi: 10.1038/sj.onc.1204536. [PubMed] [Cross Ref]
[4] Oertle T., Merkler D., Schwab M.E. Do cancer cells die because of Nogo-B? Oncogene. 2003;22:1390–1399. doi: 10.1038/sj.onc.1206278. [PubMed] [Cross Ref]
[5] Huber A.B., Weinmann O., Brosamle C., Oertle T., Schwab M.E. Patterns of Nogo mRNA and protein expression in the developing and adult rat and after CNS lesions. J Neurosci. 2002;22:3553–3567. [PubMed]
[6] Watari A., Yutsudo M. Multi-functional gene ASY/Nogo/RTNX/RTN4: apoptosis, tumor suppression, and inhibition of neuronal regeneration. Apoptosis. 2003;8:5–9. doi: 10.1023/A:1021639016300. [PubMed] [Cross Ref]
[7] Tambe Y., Isono T., Haraguchi S., Yoshioka-Yamashita A., Yutsudo M., Inoue H. A novel apoptotic pathway induced by the drs tumor suppressor gene. Oncogene. 2004;23:2977–2987. doi: 10.1038/sj.onc.1207419. [PubMed] [Cross Ref]
[8] Amberger V.R., Hensel T., Ogata N., Schwab M.E. Spreading and migration of human glioma and rat C6 cells on central nervous system myelin in vitro is correlated with tumor malignancy and involves a metalloproteolytic activity. Cancer Res. 1998;58:149–158. [PubMed]
[9] Liao H., Duka T., Teng F.Y., Sun L., Bu W.Y., Ahmed S. Nogo-66 and myelin-associated glycoprotein (MAG) inhibit the adhesion and migration of Nogo-66 receptor expressing human glioma cells. J Neurochem. 2004;90:1156–1162. doi: 10.1111/j.1471-4159.2004.02573.x. [PubMed] [Cross Ref]
[10] Oertle T., van der Haar M.E., Bandtlow C.E., Robeva A., Burfeind P., Buss A. Nogo-A inhibits neurite outgrowth and cell spreading with three discrete regions. J Neurosci. 2003;23:5393–5406. [PubMed]
[11] Tagami S., Eguchi Y., Kinoshita M., Takeda M., Tsujimoto Y. A novel protein, RTN-XS, interacts with both Bcl-XL and Bcl-2 on endoplasmic reticulum and reduces their anti-apoptotic activity. Oncogene. 2000;19:5736–5746. doi: 10.1038/sj.onc.1203948. [PubMed] [Cross Ref]
[12] Rousseau S., Peggie M., Campbell D.G., Nebreda A.R., Cohen P. Nogo-B is a new physiological substrate for MAPKAP-K2. Biochem J. 2005;391(Pt2):433–40. [PubMed]
[13] Qi B., Qi Y., Watari A., Yoshioka N., Inoue H., Minemoto Y., et al. Pro-apoptotic ASY/Nogo-B protein associates with ASYIP. J Cell Physiol. 2003;196:312–218. doi: 10.1002/jcp.10297. [PubMed] [Cross Ref]
[14] Teng F.Y., Tang B.L. No go for brain tumors? J Mol Neurosci. 2005;25:1–6. doi: 10.1385/JMN:25:1:001. [PubMed] [Cross Ref]
[15] Ghorbel M.T., Sharman G., Leroux M., Barrett T., Donovan D.M., Becker K.G. Microarray analysis reveals interleukin-6 as a novel secretory product of the hypothalamo-neurohypophyseal system. J Biol Chem. 2003;278:19280–19285. doi: 10.1074/jbc.M209902200. [PubMed] [Cross Ref]

Articles from Neuroscience Bulletin are provided here courtesy of Springer